February 23, 2015

Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus Biosciences, Inc.

December 17, 2014

Flexus Biosciences, a Cancer Immunotherapy Company Focused on Agents for the Reversal of Tumor Immunosuppression (ARTIS), Announces $38M Financing

December 17, 2014 | FierceBiotech

Amgen vet reveals stealth startup Flexus backed by $38M from Kleiner Perkins, Celgene